NRXP Earnings NRX Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–15 of 15
| Q1 2024 | 2024-03-31 | -0.74 | 2024-05-14 | 10-Q |
| Q3 2023 | 2023-09-30 | -0.35 | 2023-11-14 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.28 | 2023-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.66 | 2024-05-14 | 10-Q |
| FY 2022 | 2022-12-31 | -0.60 | 2023-03-31 | 10-K |
| Q3 2023 | 2022-09-30 | -0.45 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.32 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.21 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -1.98 | 2023-03-31 | 10-K |
| Q3 2022 | 2021-09-30 | -1.45 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.10 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.71 | 2022-05-16 | 10-Q |
| FY 2021 | 2020-12-31 | -1.51 | 2022-03-31 | 10-K |
| Q3 2021 | 2020-09-30 | -0.20 | 2021-11-15 | 10-Q |
| Q2 2021 | 2020-06-30 | -0.04 | 2021-08-16 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.